The functional synergy shown here, between the CK2 inhibitor and daunorubicin in suppressing BCL-XL provides a mechanistic basis for testing CK2 inhibitors combined with anthracycline therapy for the treatment of AML. Here, BCL2L1 is linked to acute myeloid leukemia.